{
    "nct_id": "NCT06528691",
    "official_title": "PHASE 2 Study of Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors (GLOBOTRK)",
    "inclusion_criteria": "Screening Phase\n\n* Age from birth to age <3 years at the time of diagnosis (date of surgical resection/biopsy)\n* Participant with presumed newly diagnosed tumor in the supratentorial compartment\n* Patient must have measurable disease based on RAPNO criteria\n* ≤42 days since surgery (resection or biopsy)\n* Available tumor tissue for central review\n* Parent/guardian has the ability to understand and the willingness to sign a written informed consent document according to institutional guidelines\nHealthy volunteers allowed\nMust have maximum age of 3 Years",
    "exclusion_criteria": "Screening Phase\n\n* Previous exposure to cytotoxic chemotherapy or radiotherapy\n\nInclusion Criteria: COHORT 1\n\n* Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)\n* High-grade glioma (World Health Organization [WHO] grade III or IV) harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review\n* Patients must have measurable disease as defined by RAPNO criteria\n* Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation\n* ≤28 days since study screening\n* Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks\n* Neurologic deficits must have been stable for at least 7 days prior to study enrollment\n* Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)\n* Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment)\n* Absolute neutrophil count >1,000/µL\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5x the upper limit of normal (ULN)\n* Bilirubin ≤ 1.5 x ULN\n* Adequate renal function as defined by the following age-based serum creatinine concentrations:\n\n  * 0 to <1 year: 0.5 mg/dL\n  * 1 to <2 years: 0.6 mg/dL\n  * 2 to 3 years: 0.8 mg/dL\n* Adequate cardiac function as defined by electrocardiogram (ECG) with Fridericia's corrected QT interval (QTc) ≤ 450 msec and echocardiogram left ventricular ejection fraction (LVEF) >50%\n* Screening and enrollment consents signed\n* Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures\n\nInclusion Criteria: COHORT 2\n\n* Patients must be <3 years of age at the time of diagnosis (date of surgical resection/biopsy)\n* CNS tumor other than HGG harboring NTRK1/2/3 or ROS1 gene fusions as determined by central pathology review\n* Patients must have measurable disease as defined by RAPNO criteria\n* Patients are eligible at the time of diagnosis, prior to any exposure to chemotherapy, targeted therapy, immunotherapy, cellular therapy or radiation\n* ≤28 days since study screening\n* Lansky score ≥50% and a minimum life expectancy of ≥ 12 weeks\n* Neurologic deficits must have been stable for at least 7 days prior to study enrollment.\n* Hemoglobin ≥ 8 g/dL (without transfusion or erythropoietin use within 7 days prior to enrollment)\n* Platelet count ≥ 75,000/µL (without transfusion within 7-day period prior to enrollment);\n* Absolute neutrophil count >1,000/µL.\n* ALT and ALT ≤2.5x the upper limit of normal (ULN)\n* Bilirubin ≤ 1.5 x ULN\n* Adequate renal function as defined by the following age-based serum creatinine concentrations:\n\n  * 0 to <1 year: 0.5 mg/dL\n  * 1 to <2 years: 0.6 mg/dL\n  * 2 to 3 years: 0.8 mg/dL\n* Adequate cardiac function as defined by ECG with QTc ≤ 450 msec and echocardiogram LVEF >50%\n* Screening and enrollment consents signed\n* Willingness and ability to comply with treatment plan, scheduled visits, laboratory tests and other study procedures\n\nExclusion Criteria: COHORT 1 AND 2\n\n* Clinically significant medical disorder that could compromise the ability to tolerate study therapy or would interfere with the study procedures or results history\n* History of recent (3 months) symptomatic congestive heart failure\n* Known active, uncontrolled infection (bacterial, fungal, or viral)\n* Receiving enzyme inducing antiepileptic drugs (EIAEDs)\n* Any prior cancer therapy including chemotherapy (excluding Bridging Chemotherapy Cycle), targeted therapy, immunotherapy, cellular therapy, or radiation\n* Receiving another investigational agent concurrently\n* Surgery within 2 weeks prior to treatment enrollment\n* Patients with known hypersensitivity to excipients of the investigational medicinal product\n* Active gastrointestinal disease or malabsorption disorder (e.g. Crohn's disease, ulcerative colitis, short-gut syndrome) that would impair drug absorption\n* Inability to take medication enterally",
    "miscellaneous_criteria": ""
}